BSL3 Enhancements for RNA Virus Pandemic Preparedness

BSL3 针对 RNA 病毒大流行防范的增强

基本信息

批准号：
10611745
负责人：
Hardy Kornfeld
金额：
$ 399.42万
依托单位：
UNIV OF MASSACHUSETTS MED SCH WORCESTER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-16 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10611745
关键词：
2019-nCoV Address Air Alphavirus Ambulatory Care Animals Avian Influenza A Virus Award Back Basic Science Biotechnology COVID-19 COVID-19 pandemic Carbon Dioxide Chikungunya virus Clinical Research Clinical Trials Communicable Diseases Communication Complement Coronavirus Department of Defense Drug resistance Ensure Equipment FDA approved Faculty Foundations Freezing Funding Goals Hamsters Hantavirus Housing Immune Immunoglobulin A In Vitro Incubators Infectious Diseases Research Innovative Therapy Institutes Institution Integration Host Factors International Laboratories Manuscripts Massachusetts Modernization Nature Newcastle disease virus Pathogenicity Patients Positioning Attribute Prevention Prevention strategy Privatization Procedures Productivity Protocols documentation RNA RNA Viruses RNA vaccine Research Research Institute Research Personnel Research Project Grants Resources SARS coronavirus SARS-CoV-2 pathogenesis Safety Sampling Security Services Site Structure System Therapeutic Time Translating Translational Research United States National Institutes of Health Universities Update Virus Diseases Virus-like particle Work Zika Virus base bench to bedside biosafety level 3 facility cost design experience hemorrhagic fever virus humanized mouse in vivo innovation instrument medical schools member mouse model novel operation pandemic disease pandemic preparedness pathogen pathogenic bacteria pathogenic virus programs recruit repaired research study resilience square foot therapeutic RNA translational potential translational study treatment strategy vaccine development vaccine strategy ventilation

项目摘要

Program Summary/Abstract The University of Massachusetts Chan Medical School (UMass Chan) seeks NIH G20 funding to repair, renovate, and modernize the existing Biosafety Level 3 (BSL3) and Animal BSL3 (ABSL3) facilities to enhance current research on RNA viruses of pandemic potential. As an internationally recognized leader in infectious disease research, UMass Chan has made pivotal contributions to this field, including work on the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), highly pathogenic avian influenza virus, Newcastle disease virus, and Zika virus. At the start of the coronavirus 2019 (COVID-19) pandemic, we quickly became one of the leading institutes for research and clinical trials on SARS-CoV-2. Our researchers obtained several awards from the NIH, NSF, and Department of Defense, as well as private foundations for these studies. As a leading site for COVID-19 clinical trials, UMass Chan is uniquely poised to bridge clinical and basic research studies on these RNA viruses by enabling essential research on patient samples to complement in vitro and in vivo studies. Our findings can be translated to develop novel prevention and therapeutic strategies leveraging our world-renowned RNA Therapeutics Institute, our Institute for Drug Resistance, and our partnership with MassBiologics for vaccine development, making UMass Chan a powerhouse for bench-to-bedside translational research. The UMass Chan BSL3 Core Laboratories have seen a staggering increase in usage due to the pandemic. Our BSL3 and ABSL3 facilities need major updates and renovations to keep pace with our research programs and continue to provide a safe, modern, and efficient lab for BSL3 work. The last time these facilities were completely renovated was over a decade ago (2003–2005 for our ABLS3 and 2010–2014 for our BSL3). We will modernize the existing BSL3 and ABSL3 facilities by updating the ceiling and ventilation systems, installing new autoclaves, maximizing the existing footprint by removing outdated equipment, and updating cameras for safety. These updates will significantly enhance research on RNA viruses of pandemic potential by addressing deficiencies that have caused prolonged downtime for repairs, and by enhancing the resilience of critical building systems. Our UMass Chan Facilities and Campus Services team has extensive experience executing design, renovations, and oversight of the operations and have worked with the NIH on previous G20 and C06- funded improvements to our facilities. The G20 funding will also be backed by strong institutional support for this project and a commitment to fully equip the updated space with state-of-the-art scientific instruments and other equipment needed to maintain the productivity of currently funded and future research on SARS-CoV-2 and other BSL3-level RNA viral pathogens. With G20 funding, our BSL3 and ABSL3 labs can get much- needed updates to support our faculty as they continue to make ground-breaking fundamental discoveries with translational potential to address SARS-CoV-2 and other RNA viruses of pandemic potential.

程序摘要/摘要马萨诸塞大学陈医学院（UMASS Chan）寻求NIH G20资金来维修，翻新，现代化现有的生物安全3级（BSL3）和动物BSL3（ABSL3）设施以增强当前对大流行潜力的RNA病毒的研究。作为国际公认的传染性领导者疾病研究，UMass Chan对该领域做出了关键贡献，包括严重急性的工作呼吸综合征冠状病毒2（SARS-COV-2），高度致病的禽类，纽卡斯尔病病毒和寨卡病毒。在2019年冠状病毒（Covid-19）开始时，我们很快成为了其中之一领先的SARS-COV-2研究和临床试验研究所。我们的研究人员从 NIH，NSF和国防部以及这些研究的私人基金会。作为领先地点 COVID-19临床试验，UMass Chan在桥接这些研究方面被弥合有关这些的临床和基础研究 RNA病毒通过使患者样品的基本研究能够完成体外和体内研究。我们的可以翻译发现以制定新颖的预防和治疗策略，以利用我们的世界知名度 RNA疗法研究所，我们的耐药性研究所以及我们与疫苗大众的合作伙伴关系开发，使UMASS Chan成为卧铺对床位翻译研究的强大力量。由于大流行，UMass Chan BSL3核心实验室的使用量惊人。我们的BSL3和ABSL3设施需要重大更新和翻新，以使我们的研究计划保持空间并继续为BSL3工作提供安全，现代和高效的实验室。这些设施上次是完全改革是十多年前（我们的ABLS3和2010-2014的BSL3 2003 - 2005年）。我们将通过更新天花板和通风系统，安装现有的BSL3和ABSL3设施现代化新的高压灭绝，通过卸下过时的设备来最大化现有的足迹，并更新相机安全。这些更新将通过解决有关大流行潜力的RNA病毒的研究导致停机时间长时间维修的缺陷，并通过增强关键的弹性建筑系统。我们的UMass Chan设施和校园服务团队拥有丰富的经验执行对操作的设计，翻新和监督，并与NIH合作了以前的G20和C06-- 资助了我们设施的改进。 G20资金还将得到强大的机构支持的支持该项目以及致力于充分装备更新的空间，并配备最先进的科学工具和维持有关SARS-COV-2的当前资助和未来研究所需的其他设备和其他BSL3级RNA病毒病原体。借助G20资金，我们的BSL3和ABSL3实验室可以得到很多需要更新以支持我们的教师，因为他们继续与解决SARS-COV-2和其他大流行潜力的RNA病毒的转化潜力。